Mapping the off-target effects of every FDA-approved drug in existence (EvE Bio)

Note: Thank you to Bill Busa, CEO and co-founder of EvE Bio, for an extremely helpful discussion while working on this essay. This essay is long, and I recognize that many people don’t necessarily care about the details. The real headline point you need to be aware of is this dataset, which was produced by EvE Bio underneath a CC-NA license, and is a comprehensive mapping of the interactions between a significant fraction of clinically important human cellular receptors and 1,600~ FDA-approved drugs. I strongly believe that this data is really, really useful, and more people should be aware it exists. If you’d like to understand why I think it is useful, and what the dataset exactly contains, read on! Introduction Why is understanding off-target effects important? Drug repurposing Validation data for models (Maybe) Polypharmacology How do you understand off-target effects in a tractable way? Why hasn’t anyone done this before? What does the future look like? If you were to be a fly on

Note: Thank you to Bill Busa, CEO and co-founder of EvE Bio, for an extremely helpful discussion while working on this essay. This essay is long, and I recognize that many people don’t necessarily care about the details. The real headline point you need to be aware of is this dataset, which was produced by EvE Bio underneath a CC-NA license, and is a comprehensive mapping of the interactions between a significant fraction of clinically important human cellular receptors and 1,600~ FDA-approved drugs. I strongly believe that this data is really, really useful, and more people should be aware it